Fibromyalgia Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Fibromyalgia Treatment Market: By Treatment Method (Anti-depressants, Anticonvulsants, Muscle Relaxants, Analgesics, and Wearables)), Distribution Channel (Hospitals, Retail Pharmacies, and Online Pharmacies), and Geographical Location (North America, Europe, Asia-Pacific, Latin America, Middle East, And Africa) And Forecast To 2028

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Fibromyalgia Treatment Market size is valued at USD 3,017.9 million in 2021 and poised to grow at a significant CAGR of 3.8% within the forecast period of 2022-2028. A musculoskeletal illness called fibromyalgia is distinguished by severe pain, which is frequently accompanied by sleep problems, exhaustion, mood fluctuations, and memory loss. Only three medications have currently been explicitly licensed for the treatment of fibromyalgia. As a result, off-label products are used more frequently to control the disease. But it’s anticipated that increased research and development in pain management will support the use of approved medications adherence for the illness indication. For example, 21 clinical studies are now being done to evaluate the various therapy options for fibromyalgia, according to clinicaltrials.gov. The increased research can propel the fibromyalgia treatment market size in the forecast period.  The expansion of the worldwide fibromyalgia treatment market is fueled by a number of factors. However, the primary factor projected to grow the market is the rise in fibromyalgia on a global scale. Around five million Americans who are 18 years of age or older and have fibromyalgia, according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), suffer from the condition. Furthermore, between 80 and 90 percent of fibromyalgia patients are women. Additionally, it is anticipated that rising government measures to educate businesses and medical professionals about fibromyalgia will boost market expansion. For instance, the European League Against Rheumatism (EULAR) advised against using non-steroidal anti-inflammatory medicines (NSAID) to treat fibromyalgia in their 2016 guidelines. These regulations are anticipated to raise awareness and assist those who suffer from fibromyalgia in managing their condition. Moreover, to maintain their market position, established firms with a monopoly on the market are actively involved in the introduction of cutting-edge fibromyalgia remedies. Thus, the fibromyalgia treatment drug market is anticipated to increase faster than expected throughout the forecast period due to upcoming releases and authorizations that concentrate on the treatment of fibromyalgia. Only three medications are currently explicitly licensed for the treatment of fibromyalgia. As a result, off-label medications and generic antidepressants are being used more frequently to treat the disease’s symptoms. Furthermore, Pfizer lost its right to patent-protect Lyrica in June 2019. The drug’s market revenue has been significantly damaged by this patent expiration. According to fibromyalgia treatment market analysis, generic competition will impede market expansion in the foreseeable future.

Critical Developments in Fibromyalgia Treatment Market:

In May 2022, FDA approves NeuroMetrix’s wearable neuromodulator as the first non-drug fibromyalgia treatment

In August 2021, Swing Therapeutics, a digital therapeutics business, has been recognized as an effective way possible by the FDA for its 12-week smartphone-assisted fibromyalgia management program.

Fibromyalgia Treatment Market

MARKET SUMMARY
-
3.8%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 3.8%
  • Largest Market– Asia Pacific
  • Fastest Growing Market– North America

Fibromyalgia Treatment Market

  • The global fibromyalgia treatment market report gives a comprehensive outlook across the globe with particular emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.
  • The report on the global fibromyalgia treatment market gives historical, current, and future market sizes based on treatment method, distribution channel, and geography
Key Players
  • Abbott
  • AbbVie
  • Allergan
  • AstraZeneca
  • Bayer AG
Fibromyalgia Treatment Market Dynamics

In the United States, fibromyalgia is thought to impact 10 million people, and it is thought to afflict 3% to 6% of the world’s population. In children, adults, and both sexes, this illness is identified and frequently observed, with women accounting for 75%–90% of all FM patients (Source: National Fibromyalgia Association (NFA)). Additionally, the estimated prevalence of fibromyalgia in the United Kingdom is 5.4%, roughly 1 in every 20 persons (Source: Versus Arthritis, 2019). Due to the disease’s high incidence, there will likely be greater demand for improved care as well as potent drugs that reduce the pain and tenderness that come along with it. So, it is anticipated that the desire for better fibromyalgia treatments will positively influence fibromyalgia treatment market growth. There are currently very few medicines that have been licensed for treating fibromyalgia, despite its growing prevalence worldwide. Thus, in order to serve the more significant patient population, numerous top industry firms are involved in the research and development of new pharmaceuticals. These efforts have produced promising results, earning approval to progress the drugs from the early stages of the trial to advanced phases. For instance, there are numerous possible therapeutic candidates undergoing phase 2 and phase 3 clinical studies, including ICM 1 (Viros Therapeutics), NYX-2925 (Aptinyx), DS-5565 (Daichi Sankyo), and TD-9855 (Theravance Biopharma). Thus, in the following years, it is anticipated that the availability of treatments with the potential for commercialization will accelerate the expansion of the worldwide fibromyalgia treatment market. Leading players will also be able to boost their current portfolios and increase their global footprint as a result of such changes.


North-America Got Significant Share

Fibromyalgia Treatment Market

North America generated USD 1,065.3 million in revenue in 2021 and will lead market growth over the forecast period. The advancement is due to the increased detection and frequency of fibromyalgia, as well as the increased availability of cutting-edge approved medicines to control the disease. Fibromyalgia affects an estimated 2-4% of Americans, according to the American Chronic Pain Association (2017). Furthermore, the increased focus of key competitors on launching novel pharmaceuticals in the North American area is expected to boost the fibromyalgia treatment drug market throughout the forecast period. The increased prevalence of fibromyalgia is one of the factors driving market growth in Europe. Furthermore, the lack of fibromyalgia treatment choices and new product introductions are expected to boost the fibromyalgia treatment market growth in the upcoming years. Furthermore, an increase in healthcare spending by the European Commission is expected to propel the region's growth. Meanwhile, the Asia-Pacific market is expected to rise steadily over the forecast period. Aspects such as the growing fibromyalgia patient population, rising healthcare expenditure, and improving healthcare infrastructure are expected to promote market growth in the Asia Pacific. Increasing fibromyalgia awareness is expected to drive the market during the forecast period.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The fibromyalgia treatment market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and startup details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Fibromyalgia Treatment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The fibromyalgia treatment market is projected to expand at a CAGR of 3.8% during the forecast period

Abbott, AbbVie, Allergan, Astellas Pharma, AstraZeneca, Bayer AG, Boehringer Ingelheim

North America is the fastest-growing region for the fibromyalgia treatment market


Report

Table Of Content

1. Executive Summary
2. Global Fibromyalgia Treatment Market Introduction
2.1. Global Fibromyalgia Treatment Market – Taxonomy
2.2. Global Fibromyalgia Treatment Market –Definitions
2.2.1. By Treatment Method
2.2.2. By Distribution Channel
2.2.3. By Region
3. Global Fibromyalgia Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Fibromyalgia Treatment Market Dynamic Factors – Impact Analysis
3.6. Global Fibromyalgia Treatment Market – Competition Landscape
3.7. Epidemiology
4. Global Fibromyalgia Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Fibromyalgia Treatment Market, By Treatment Method, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Anti-depressants
5.1.1. Venlafaxine
5.1.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Duloxetine
5.1.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Milnacipran HCL
5.1.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.1.4. Others
5.1.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.4.3. Market Opportunity Analysis
5.2. Anticonvulsants
5.2.1. Pregabalin
5.2.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Gabapentin
5.2.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.3. Muscle Relaxants
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Analgesics
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Wearables
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. Global Fibromyalgia Treatment Market, By Distribution Channel, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1. Hospitals
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Online Pharmacies
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Fibromyalgia Treatment Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Fibromyalgia Treatment Market – Opportunity Analysis Index, By Treatment Method, By Distribution Channel, and Region, 2022 – 2028
8. North America Fibromyalgia Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1. Treatment Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Anti-depressants
8.1.1.1. Venlafaxine
8.1.1.2. Duloxetine
8.1.1.3. Milnacipran HCL
8.1.1.4. Others
8.1.2. Anticonvulsants
8.1.2.1. Pregabalin
8.1.2.2. Gabapentin
8.1.3. Muscle Relaxants
8.1.4. Analgesics
8.1.5. Wearables
8.2. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Hospitals
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Fibromyalgia Treatment Market – Opportunity Analysis Index, By Treatment Method, By Distribution Channel, and Country, 2022 – 2028
8.5. North America Fibromyalgia Treatment Market Dynamics – Trends
9. Europe Fibromyalgia Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. Treatment Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Anti-depressants
9.1.1.1. Venlafaxine
9.1.1.2. Duloxetine
9.1.1.3. Milnacipran HCL
9.1.1.4. Others
9.1.2. Anticonvulsants
9.1.2.1. Pregabalin
9.1.2.2. Gabapentin
9.1.3. Muscle Relaxants
9.1.4. Analgesics
9.1.5. Wearables
9.2. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Hospitals
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Rest of Europe
9.4. Europe Fibromyalgia Treatment Market – Opportunity Analysis Index, By Treatment Method, By Distribution Channel, and Country, 2022 – 2028
9.5. Europe Fibromyalgia Treatment Market Dynamics – Trends
10. Asia-Pacific Fibromyalgia Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Treatment Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Anti-depressants
10.1.1.1. Venlafaxine
10.1.1.2. Duloxetine
10.1.1.3. Milnacipran HCL
10.1.1.4. Others
10.1.2. Anticonvulsants
10.1.2.1. Pregabalin
10.1.2.2. Gabapentin
10.1.3. Muscle Relaxants
10.1.4. Analgesics
10.1.5. Wearables
10.2. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Hospitals
10.2.2. Retail Pharmacies
10.2.3. Online Pharmacies
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Fibromyalgia Treatment Market – Opportunity Analysis Index, By Treatment Method, By Distribution Channel, and Country, 2022 – 2028
10.5. Asia-Pacific Fibromyalgia Treatment Market Dynamics – Trends
11. Latin America Fibromyalgia Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. Treatment Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Anti-depressants
11.1.1.1. Venlafaxine
11.1.1.2. Duloxetine
11.1.1.3. Milnacipran HCL
11.1.1.4. Others
11.1.2. Anticonvulsants
11.1.2.1. Pregabalin
11.1.2.2. Gabapentin
11.1.3. Muscle Relaxants
11.1.4. Analgesics
11.1.5. Wearables
11.2. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Hospitals
11.2.2. Retail Pharmacies
11.2.3. Online Pharmacies
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Latin America Fibromyalgia Treatment Market – Opportunity Analysis Index, By Treatment Method, By Distribution Channel, and Country, 2022 – 2028
11.5. Latin America Fibromyalgia Treatment Market Dynamics – Trends
12. Middle East and Africa Fibromyalgia Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. Treatment Method Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Anti-depressants
12.1.1.1. Venlafaxine
12.1.1.2. Duloxetine
12.1.1.3. Milnacipran HCL
12.1.1.4. Others
12.1.2. Anticonvulsants
12.1.2.1. Pregabalin
12.1.2.2. Gabapentin
12.1.3. Muscle Relaxants
12.1.4. Analgesics
12.1.5. Wearables
12.2. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Hospitals
12.2.2. Retail Pharmacies
12.2.3. Online Pharmacies
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Fibromyalgia Treatment Market – Opportunity Analysis Index, By Treatment Method, By Distribution Channel, and Country, 2022 – 2028
12.5. MEA Fibromyalgia Treatment Market Dynamics – Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Abbott
13.2.2. AbbVie
13.2.3. Allergan
13.2.4. Astellas Pharma
13.2.5. AstraZeneca
13.2.6. Bayer AG
13.2.7. Boehringer Ingelheim
13.2.8. Cephalon, Inc.
13.2.9. Eli Lilly
13.2.10. F. Hoffmann-La Roche
13.2.11. GlaxoSmithKline
13.2.12. Johnson & Johnson Services
13.2.13. Novartis
13.2.14. Pfizer
13.2.15. Sanofi
14. Research Methodology
15. Key Assumptions and Acronyms

Report

Company Profile

  • Abbott
  • AbbVie
  • Allergan
  • Astellas Pharma
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Cephalon, Inc.
  • Eli Lilly
  • Hoffmann-La Roche
  • GlaxoSmithKline
  • Johnson & Johnson Services
  • Novartis
  • Pfizer
  • Sanofi

Description

Fibromyalgia Treatment Market size is valued at USD 3,017.9 million in 2021 and poised to grow at a significant CAGR of 3.8% within the forecast period of 2022-2028. A musculoskeletal illness called fibromyalgia is distinguished by severe pain, which is frequently accompanied by sleep problems, exhaustion, mood fluctuations, and memory loss. Only three medications have currently been explicitly licensed for the treatment of fibromyalgia. As a result, off-label products are used more frequently to control the disease. But it’s anticipated that increased research and development in pain management will support the use of approved medications adherence for the illness indication. For example, 21 clinical studies are now being done to evaluate the various therapy options for fibromyalgia, according to clinicaltrials.gov. The increased research can propel the fibromyalgia treatment market size in the forecast period.  The expansion of the worldwide fibromyalgia treatment market is fueled by a number of factors. However, the primary factor projected to grow the market is the rise in fibromyalgia on a global scale. Around five million Americans who are 18 years of age or older and have fibromyalgia, according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), suffer from the condition. Furthermore, between 80 and 90 percent of fibromyalgia patients are women. Additionally, it is anticipated that rising government measures to educate businesses and medical professionals about fibromyalgia will boost market expansion. For instance, the European League Against Rheumatism (EULAR) advised against using non-steroidal anti-inflammatory medicines (NSAID) to treat fibromyalgia in their 2016 guidelines. These regulations are anticipated to raise awareness and assist those who suffer from fibromyalgia in managing their condition. Moreover, to maintain their market position, established firms with a monopoly on the market are actively involved in the introduction of cutting-edge fibromyalgia remedies. Thus, the fibromyalgia treatment drug market is anticipated to increase faster than expected throughout the forecast period due to upcoming releases and authorizations that concentrate on the treatment of fibromyalgia. Only three medications are currently explicitly licensed for the treatment of fibromyalgia. As a result, off-label medications and generic antidepressants are being used more frequently to treat the disease’s symptoms. Furthermore, Pfizer lost its right to patent-protect Lyrica in June 2019. The drug’s market revenue has been significantly damaged by this patent expiration. According to fibromyalgia treatment market analysis, generic competition will impede market expansion in the foreseeable future.

Critical Developments in Fibromyalgia Treatment Market:

In May 2022, FDA approves NeuroMetrix’s wearable neuromodulator as the first non-drug fibromyalgia treatment

In August 2021, Swing Therapeutics, a digital therapeutics business, has been recognized as an effective way possible by the FDA for its 12-week smartphone-assisted fibromyalgia management program.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX